© 1995 by Oxford University Press
Journal of the National Cancer Institute, Vol. 87, No. 10, 751-756,
May 17, 1995
© 1995 Oxford University Press
Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1: Predictors of Poor Response to Tamoxifen Therapy in Recurrent Breast Cancer
Division of Endocrine Oncology, Department of Medical Oncology, Dr. Daniel den Hoed Cancer Center Rotterdam, The Netherlands
Department of Statistics, Dr. Daniel den Hoed Cancer Center Rotterdam, The Netherlands
Correspondence to: John A. Foekens, Ph.D., Dr. Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 AE Rotterdam, The Netherlands.
Background: Urokinase-type plasminogen activator (uPA) is a proteolytic enzyme thought to be involved in processes leading to tumor cell invasion of surrounding tissues. Its activity during metastasis may be regulated by an inhibitor, PAI-1. Previous work has shown that high levels of uPA and PAI-1 are associated with poor prognosis in primary breast cancers. Purpose: In this pilot study, we explored possible associations between the expression levels of uPA or PAI-1 and the efficacy of tamoxifen treatment in breast cancer patients with relapsed disease. Methods: Levels of uPA, PAI-1, estrogen receptor (ER), and progesterone receptor (PgR) were assayed in cytosolic extracts derived from the primary breast tumors of 235 tamoxifennaive patients who had recurrent disease. The extracts were classified as positive or negative for each assayed factor. In some analyses, ER and PgR levels were evaluated together. In these analyses, three ER/PgR subsets were defined: low, intermediate, and high. All patients in the study received tamoxifen therapy upon relapse (median follow-up, 57 months). Association of the tested factors with the response to tamoxifen treatment was studied by logistic regression analysis. Association of the factors with progression-free and overall survival was further evaluated by Cox univariate and multivariate regression analyses. Results: Patients with uPA-negative tumors exhibited a better response (tumor regression or stable disease, maintained for more than 6 months) to tamoxifen treatment than those with uPA-positive tumors (51% versus 26% response; odds ratio [OR] = 0.34; 95% confidence interval [CI] = 0.18–0.65). The response rate was also better for patients with PAI-1-negative tumors than for those with PAI-1-positive tumors (49% versus 35% response; OR = 0.57; 95% CI = 0.32–1.01). In addition, patients with uPA-positive or PAI-1-positive tumors showed shorter progression-free survival (P =.001 and P<.05, respectively) and total survival after relapse (P =.005 and P<.005, respectively). When patients were stratified by ER/PgR status, the only statistically significant association between uPA levels and reduced tamoxifen response was seen in the subset whose tumors possessed intermediate levels of ER/PgR (16% response in uPA-positive versus 60% response in uPA-negative tumors; OR = 0.13; 95% CI = 0.04–0.41). Overall, uPA status appeared independent of association with ER/PgR status in its ability to predict response to tamoxifen treatment. The association of PAI-1 expression and the response to tamoxifen was less pronounced when patients were stratified by ER/PgR status. Conclusion: Measurement of primary breast tumor uPA levels may be useful in predicting the overall response of metastatic disease to tamoxifen therapy. [J Natl Cancer Inst 87: 751–756, 1995]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Meijer, A. M Sieuwerts, M. P Look, T. van Agthoven, J. A Foekens, and L. C J Dorssers Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer Endocr. Relat. Cancer, March 1, 2008; 15(1): 101 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-S. Schrohl, M. E. Meijer-van Gelder, M. N. Holten-Andersen, I. J. Christensen, M. P. Look, H. T. Mouridsen, N. Brunner, and J. A. Foekens Primary Tumor Levels of Tissue Inhibitor of Metalloproteinases-1 Are Predictive of Resistance to Chemotherapy in Patients with Metastatic Breast Cancer Clin. Cancer Res., December 1, 2006; 12(23): 7054 - 7058. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhang, X.-O. Shu, Q. Cai, Z. Ruan, Y.-T. Gao, and W. Zheng Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival. Clin. Cancer Res., October 15, 2006; 12(20): 6037 - 6042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Sieuwerts, M. E. Meijer-van Gelder, M. Timmermans, A. M.A.C. Trapman, R. R. Garcia, M. Arnold, A. J.W. Goedheer, H. Portengen, J. G.M. Klijn, and J. A. Foekens How ADAM-9 and ADAM-11 Differentially From Estrogen Receptor Predict Response to Tamoxifen Treatment in Patients with Recurrent Breast Cancer: a Retrospective Study Clin. Cancer Res., October 15, 2005; 11(20): 7311 - 7321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Duffy Predictive Markers in Breast and Other Cancers: A Review Clin. Chem., March 1, 2005; 51(3): 494 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. M.-v. Gelder, M. P. Look, H. A. Peters, M. Schmitt, N. Brunner, N. Harbeck, J. G. M. Klijn, and J. A. Foekens Urokinase-Type Plasminogen Activator System in Breast Cancer: Association with Tamoxifen Therapy in Recurrent Disease Cancer Res., July 1, 2004; 64(13): 4563 - 4568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Manders, V. C. G. Tjan-Heijnen, P. N. Span, N. Grebenchtchikov, J. A. Foekens, L. V. A. M. Beex, and C. G. J. Sweep Predictive Impact of Urokinase-Type Plasminogen Activator: Plasminogen Activator Inhibitor Type-1 Complex on the Efficacy of Adjuvant Systemic Therapy in Primary Breast Cancer Cancer Res., January 15, 2004; 64(2): 659 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. J. J. Berns, J. G. M. Klijn, M. P. Look, N. Grebenchtchikov, R. Vossen, H. Peters, A. Geurts-Moespot, H. Portengen, I. L. van Staveren, M. E. Meijer-van Gelder, et al. Combined Vascular Endothelial Growth Factor and TP53 Status Predicts Poor Response to Tamoxifen Therapy in Estrogen Receptor-positive Advanced Breast Cancer Clin. Cancer Res., April 1, 2003; 9(4): 1253 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Burger, J. A. Foekens, M. P. Look, M. E. Meijer-van Gelder, J. G. M. Klijn, E. A. C. Wiemer, G. Stoter, and K. Nooter RNA Expression of Breast Cancer Resistance Protein, Lung Resistance-related Protein, Multidrug Resistance-associated Proteins 1 and 2, and Multidrug Resistance Gene 1 in Breast Cancer: Correlation with Chemotherapeutic Response Clin. Cancer Res., February 1, 2003; 9(2): 827 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Harbeck, R. E. Kates, M. P. Look, M. E. Meijer-van Gelder, J. G. M. Klijn, A. Kruger, M. Kiechle, F. Janicke, M. Schmitt, and J. A. Foekens Enhanced Benefit from Adjuvant Chemotherapy in Breast Cancer Patients Classified High-Risk according to Urokinase-type Plasminogen Activator (uPA) and Plasminogen Activator Inhibitor Type 1 (n = 3424) Cancer Res., August 15, 2002; 62(16): 4617 - 4622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Duffy Urokinase Plasminogen Activator and Its Inhibitor, PAI-1, as Prognostic Markers in Breast Cancer: From Pilot to Level 1 Evidence Studies Clin. Chem., August 1, 2002; 48(8): 1194 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Harbeck, R. E. Kates, and M. Schmitt Clinical Relevance of Invasion Factors Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 for Individualized Therapy Decisions in Primary Breast Cancer Is Greatest When Used in Combination J. Clin. Oncol., February 15, 2002; 20(4): 1000 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Look, W. L. J. van Putten, M. J. Duffy, N. Harbeck, I. J. Christensen, C. Thomssen, R. Kates, F. Spyratos, M. Ferno, S. Eppenberger-Castori, et al. Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients J Natl Cancer Inst, January 16, 2002; 94(2): 116 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Harbeck, U. Alt, U. Berger, A. Kruger, C. Thomssen, F. Janicke, H. Hofler, R. E. Kates, and M. Schmitt Prognostic Impact of Proteolytic Factors (Urokinase-Type Plasminogen Activator, Plasminogen Activator Inhibitor 1, and Cathepsins B, D, and L) in Primary Breast Cancer Reflects Effects of Adjuvant Systemic Therapy Clin. Cancer Res., September 1, 2001; 7(9): 2757 - 2764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Janicke, A. Prechtl, C. Thomssen, N. Harbeck, C. Meisner, M. Untch, C. G. J. F. Sweep, H.-K. Selbmann, H. Graeff, and M. Schmitt Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 J Natl Cancer Inst, June 20, 2001; 93(12): 913 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Foekens, S. Romain, M. P. Look, P.-M. Martin, and J. G. M. Klijn Thymidine Kinase and Thymidylate Synthase in Advanced Breast Cancer: Response to Tamoxifen and Chemotherapy Cancer Res., February 1, 2001; 61(4): 1421 - 1425. [Abstract] [Full Text]
|
|
|
|
|
|
E. M. J. J. Berns, J. A. Foekens, R. Vossen, M. P. Look, P. Devilee, S. C. Henzen-Logmans, I. L. van Staveren, W. L. J. van Putten, M. Inganäs, M. E. M.-v. Gelder, et al. Complete Sequencing of TP53 Predicts Poor Response to Systemic Therapy of Advanced Breast Cancer Cancer Res., April 1, 2000; 60(8): 2155 - 2162. [Abstract] [Full Text]
|
|
|
|
|
|
J. A. Foekens, H. A. Peters, M. P. Look, H. Portengen, M. Schmitt, M. D. Kramer, N. Brünner, F. Jänicke, M. E. M.-v. Gelder, S. C. Henzen-Logmans, et al. The Urokinase System of Plasminogen Activation and Prognosis in 2780 Breast Cancer Patients Cancer Res., February 1, 2000; 60(3): 636 - 643. [Abstract] [Full Text]
|
|
|
|
|
|
S. v. d. Flier, A. Brinkman, M. P. Look, E. M. Kok, M. E. Meijer-van Gelder, J. G. M. Klijn, L. C. J. Dorssers, and J. A. Foekens Bcar1/p130Cas Protein and Primary Breast Cancer: Prognosis and Response to Tamoxifen Treatment J Natl Cancer Inst, January 19, 2000; 92(2): 120 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Meijer-van Gelder, M. P. Look, J. B.-d. Vries, H. A. Peters, J. G.M. Klijn, and J. A. Foekens Breast-Conserving Therapy: Proteases as Risk Factors in Relation to Survival After Local Relapse J. Clin. Oncol., May 1, 1999; 17(5): 1449 - 1449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Sugiura, L. Ma, B. Sun, H. Shimada, W. E. Laug, R. C. Seeger, and Y. A. DeClerck The Plasminogen-Plasminogen Activator (PA) System in Neuroblastoma: Role of PA Inhibitor-1 in Metastasis Cancer Res., March 1, 1999; 59(6): 1327 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Duffy, C. Duggan, H. E. Mulcahy, E. W. McDermott, and N. J. O'Higgins Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease Clin. Chem., June 1, 1998; 44(6): 1177 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Lox, C. A. Ronaghan, E. Cobos, and R. H. Messer Tamoxifen-Induced Changes in the Plasma Fibrinolytic Factors in Menopausal Women with Breast Cancer Clinical and Applied Thrombosis/Hemostasis, October 1, 1997; 3(4): 234 - 238. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Urban, T. Golden, I. V. Aragon, J. G. Scammell, N. M. Dean, and R. E. Honkanen Identification of an Estrogen-inducible Phosphatase (PP5) That Converts MCF-7 Human Breast Carcinoma Cells into an Estrogen-independent Phenotype when Expressed Constitutively J. Biol. Chem., July 13, 2001; 276(29): 27638 - 27646. [Abstract] [Full Text] [PDF]
|
|